#MGH #LungTxp #Transplantsky #Pulmsky #ISHLT
@mgh-id.bsky.social
#MGH #LungTxp #Transplantsky #Pulmsky #ISHLT
@mgh-id.bsky.social
Different options (Abdominal / A, Thoraco-Abdominal / TA, or rapid retrieval ⚡️) & different rules across the 🌎 ➡️ lots of heterogeneity
~ Dr. Campo-Cañaeral de la Cruz (Madrid)
Different options (Abdominal / A, Thoraco-Abdominal / TA, or rapid retrieval ⚡️) & different rules across the 🌎 ➡️ lots of heterogeneity
~ Dr. Campo-Cañaeral de la Cruz (Madrid)
- Donor characteristics
- Logistics (resource intensity and "dry runs")
- Limited protocols / guidelines
- Technique options (?re-intubation, ?EVLP, ?NRP)
~ Dr. Kukreja (UCSF)
- Donor characteristics
- Logistics (resource intensity and "dry runs")
- Limited protocols / guidelines
- Technique options (?re-intubation, ?EVLP, ?NRP)
~ Dr. Kukreja (UCSF)
- In most countries, 5 minutes after circulatory arrest ⏰; but longer in others.
- Key 🔑 to ensure we are not ❌ interfering with death process through transplant ♻️.
~ Dr. Rubino (Royal Papworth)
- In most countries, 5 minutes after circulatory arrest ⏰; but longer in others.
- Key 🔑 to ensure we are not ❌ interfering with death process through transplant ♻️.
~ Dr. Rubino (Royal Papworth)
Many options: from the original tool 🛠️ from the University of Wisconsin to the more modern DCD-N score (with more recent external validation!). Consider incorporating neuro-imaging findings 🩻!
~ Dr. Murala (UWSW)
Many options: from the original tool 🛠️ from the University of Wisconsin to the more modern DCD-N score (with more recent external validation!). Consider incorporating neuro-imaging findings 🩻!
~ Dr. Murala (UWSW)
1) Maximize referrals & prognosticate every potential donor
2) Consider lower P:F (& EVLP!)
3) Palliative therapies indicated with a final transition of care to comfort measures (just as we do for non-donors!)
~ Dr. Neyrinck (Leuven)
1) Maximize referrals & prognosticate every potential donor
2) Consider lower P:F (& EVLP!)
3) Palliative therapies indicated with a final transition of care to comfort measures (just as we do for non-donors!)
~ Dr. Neyrinck (Leuven)
Improving survival and a growing role for bridging from a critically ill state 🤒🌉🥳. Some potential criteria when considering lung transplant when on ECMO. HLA sensitization can occur during ECMO ~ Dr. Dilling (Loyola)
Improving survival and a growing role for bridging from a critically ill state 🤒🌉🥳. Some potential criteria when considering lung transplant when on ECMO. HLA sensitization can occur during ECMO ~ Dr. Dilling (Loyola)
Multiple vector options - viral 👾 and non-viral 🧪. Intra-tracheal 💨 or iv 💉 gene therapy during EVLP are ground-breaking approaches. CRISPR-Cas modification of donor lungs a promising potential offshoot! ~ Dr. Hartwig (Duke)
Multiple vector options - viral 👾 and non-viral 🧪. Intra-tracheal 💨 or iv 💉 gene therapy during EVLP are ground-breaking approaches. CRISPR-Cas modification of donor lungs a promising potential offshoot! ~ Dr. Hartwig (Duke)
EVLP 🤖📦 involves "perfusion" → can drive more inflammatory response 🔥📈. Watch 🫁 function closely - space for additional biomarkers 🩸 & composite evaluation tools 📋. EVLP management in 💦: modify circuit, perfusate, or ventilation 💨! ~ Dr. Rosso (Milan)
EVLP 🤖📦 involves "perfusion" → can drive more inflammatory response 🔥📈. Watch 🫁 function closely - space for additional biomarkers 🩸 & composite evaluation tools 📋. EVLP management in 💦: modify circuit, perfusate, or ventilation 💨! ~ Dr. Rosso (Milan)
Similar outcomes & mortality -> an impetus to keep considering DDD lungs ~ Dr. Balasubramanian (Mayo Clinic)
Similar outcomes & mortality -> an impetus to keep considering DDD lungs ~ Dr. Balasubramanian (Mayo Clinic)